| scholarly article | Q13442814 |
| P50 | author | Mark Shlomchik | Q29887913 |
| Warren D Shlomchik | Q88702783 | ||
| Jennifer M McNiff | Q91890099 | ||
| P2093 | author name string | Britt E Anderson | |
| Catherine Matte | |||
| Ionna Athanasiadis | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1565-1573 | |
| P577 | publication date | 2004-05-18 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease | |
| P478 | volume | 104 |
| Q35092315 | A New Zealand Black-derived locus suppresses chronic graft-versus-host disease and autoantibody production through nonlymphoid bone marrow-derived cells |
| Q52959192 | A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice. |
| Q27320513 | A bispecific protein capable of engaging CTLA-4 and MHCII protects non-obese diabetic mice from autoimmune diabetes |
| Q33829731 | A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice |
| Q49679320 | Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy |
| Q37420496 | Acute graft-versus-host disease: from the bench to the bedside |
| Q36759581 | Advances in the understanding of acute graft-versus-host disease. |
| Q34769458 | Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease |
| Q57176290 | Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation |
| Q35232833 | Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes |
| Q37294468 | Biology of chronic graft-versus-host disease: implications for a future therapeutic approach |
| Q37644959 | Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation |
| Q35994928 | CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. |
| Q36386905 | CD4+CD25+ regulatory T lymphocytes in bone marrow transplantation |
| Q92538754 | CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation |
| Q36508991 | CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. |
| Q36766430 | Chronic graft-versus-host disease in the era of reduced-intensity conditioning |
| Q39002164 | Chronic graft-versus-host disease: biological insights from preclinical and clinical studies |
| Q36585241 | Control of graft-versus-host disease by regulatory T cells: which level of antigen specificity? |
| Q34133590 | Control of homeostatic proliferation by regulatory T cells |
| Q34806652 | Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells |
| Q52954957 | Defects in regulatory T cells due to CD28 deficiency induce a qualitative change of allogeneic immune response in chronic graft-versus-host disease. |
| Q37903245 | Dendritic cells in cord blood transplantation: a review |
| Q37378659 | Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2hi NKT cells. |
| Q42920928 | Effects of Pravastatin on Murine Chronic Graft-Versus-Host Disease |
| Q36658080 | Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells |
| Q26774934 | Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications |
| Q33766995 | Engineering cord blood to improve engraftment after cord blood transplant |
| Q36453025 | Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells |
| Q37197925 | Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion |
| Q35829151 | Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras |
| Q93238177 | GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells |
| Q36793622 | Graft-versus-host disease |
| Q50332623 | Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells |
| Q84541167 | Graft-versus-host disease: who's responsible? |
| Q35680360 | Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease |
| Q35619237 | Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease |
| Q36252940 | Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States |
| Q33931910 | Hematopoietic progenitor cell regulation by CD4+CD25+ T cells |
| Q37176591 | Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease |
| Q24656069 | Human T regulatory cell therapy: take a billion or so and call me in the morning |
| Q37251057 | Immune modulation and chronic graft-versus-host disease |
| Q36434639 | Immune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantation |
| Q34400439 | Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance |
| Q37606564 | Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells |
| Q37785538 | Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood |
| Q41923994 | In situ activation and expansion of host tregs: a new approach to enhance donor chimerism and stable engraftment in major histocompatibility complex-matched allogeneic hematopoietic cell transplantation |
| Q33798249 | In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease |
| Q36843821 | In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease |
| Q34144161 | Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics |
| Q34980164 | Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice. |
| Q91994072 | Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells |
| Q40543171 | Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease. |
| Q36539693 | MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. |
| Q35194858 | Maternal microchimerism in pediatric inflammatory bowel disease |
| Q36645730 | Murine models of chronic graft-versus-host disease: insights and unresolved issues |
| Q40020268 | MyD88 signaling in CD4 T cells promotes IFN-γ production and hematopoietic progenitor cell expansion in response to intracellular bacterial infection. |
| Q35847596 | New approaches for preventing and treating chronic graft-versus-host disease |
| Q36474155 | Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli |
| Q36556498 | Optimization of allogeneic transplant conditioning: not the time for dogma |
| Q37633440 | PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas. |
| Q37776637 | Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation. |
| Q38660463 | Preclinical modeling of hematopoietic stem cell transplantation - advantages and limitations |
| Q36408216 | Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review |
| Q36056986 | Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes |
| Q37900645 | Regulatory T cells and IL-17-producing cells in graft-versus-host disease |
| Q52008998 | Regulatory T cells control autoimmunity following syngeneic bone marrow transplantation. |
| Q34314157 | Regulatory T cells in γ irradiation-induced immune suppression. |
| Q53292640 | SHIP-1 deficiency in the myeloid compartment is insufficient to induce myeloid expansion or chronic inflammation. |
| Q38625892 | Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation |
| Q36403106 | Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen |
| Q40350452 | Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding |
| Q81909390 | Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma |
| Q38416376 | State-of-the-art acute and chronic GVHD treatment |
| Q38265814 | Stem cell therapies for systemic sclerosis. |
| Q36757169 | Suppression of IL-7-dependent Effector T-cell Expansion by Multipotent Adult Progenitor Cells and PGE2. |
| Q36994811 | Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses |
| Q50647528 | The development of autoimmune features in aging mice is closely associated with alterations of the peripheral CD4⁺ T-cell compartment. |
| Q37313942 | The immunopathology of thymic GVHD. |
| Q35084404 | The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma |
| Q33792598 | Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice |
| Q34624143 | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels |
| Q34137032 | Treatment of chronic graft-versus-host disease with bortezomib |
| Q39644103 | Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous-BMT Improves the Survival of Leukemia-Challenged Mice |
| Q36907746 | Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice |
Search more.